Post-earnings recap
Reported
Fri, May 12, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
ADMA Biologics reported a loss per share of $0.51, but the stock still rose by 2.60% following the announcement. The increase in stock price may reflect investor sentiment or market conditions rather than strong financial performance, as there were no revenue figures provided. The lack of guidance and management commentary leaves uncertainty about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.51 | N/A | — |
| Revenue | N/A | N/A | — |
No transcript is on record, and the analysis is based on numerical results only.